BACKGROUND: We performed a prospective phase II trial to investigate the safety and efficacy of radiotherapy combined with capecitabine in patients suffering from a recurrence of a squamous cell carcinoma of the head and neck (SCCHN) within a previously irradiated field. PATIENTS AND METHODS: A total of 31 evaluable patients with recurrent SCCHN received re-irradiation with a total dose of 50 Gy (25 fractions over 5 weeks) up to a maximum of 60 Gy combined with 900 mg/m(2)/day capecitabine given on the days of radiotherapy. RESULTS: The median time to relapse after the first course of radiotherapy was 15 months. The overall response rate in our study was 68% including 6 patients with a complete response. The median overall survival was 8.4 months. Grade 3 or 4 mucositis occurred in 4 patients and 1 patient, respectively. No grade 4 hematological toxicities were observed; 1 patient had grade 3 anemia. The cumulative median lifetime dose was 116 Gy. CONCLUSION: Capecitabine combined with re-irradiation is a well-tolerated treatment in patients with recurrent SCCHN. In light of its good tolerability, it appears to be a potential option for patients with a reduced performance status and may also serve as a basis for novel treatment concepts, such as in combination with targeted therapies.
BACKGROUND: We performed a prospective phase II trial to investigate the safety and efficacy of radiotherapy combined with capecitabine in patients suffering from a recurrence of a squamous cell carcinoma of the head and neck (SCCHN) within a previously irradiated field. PATIENTS AND METHODS: A total of 31 evaluable patients with recurrent SCCHN received re-irradiation with a total dose of 50 Gy (25 fractions over 5 weeks) up to a maximum of 60 Gy combined with 900 mg/m(2)/day capecitabine given on the days of radiotherapy. RESULTS: The median time to relapse after the first course of radiotherapy was 15 months. The overall response rate in our study was 68% including 6 patients with a complete response. The median overall survival was 8.4 months. Grade 3 or 4 mucositis occurred in 4 patients and 1 patient, respectively. No grade 4 hematological toxicities were observed; 1 patient had grade 3 anemia. The cumulative median lifetime dose was 116 Gy. CONCLUSION:Capecitabine combined with re-irradiation is a well-tolerated treatment in patients with recurrent SCCHN. In light of its good tolerability, it appears to be a potential option for patients with a reduced performance status and may also serve as a basis for novel treatment concepts, such as in combination with targeted therapies.
Authors: A W Lee; W Foo; S C Law; Y F Poon; W M Sze; S K O; S Y Tung; W H Lau Journal: Int J Radiat Oncol Biol Phys Date: 1997-04-01 Impact factor: 7.038
Authors: A I Dreyfuss; J R Clark; C M Norris; R M Rossi; J W Lucarini; P M Busse; M D Poulin; L Thornhill; R Costello; M R Posner Journal: J Clin Oncol Date: 1996-05 Impact factor: 44.544
Authors: A Jegannathen; K Mais; A Sykes; L Lee; B Yap; A Birzgalis; J Homer; W D Ryder; N Slevin Journal: Clin Oncol (R Coll Radiol) Date: 2010-10-14 Impact factor: 4.126
Authors: D M Shin; F R Khuri; B S Glisson; L Ginsberg; V M Papadimitrakopoulou; G Clayman; J J Lee; K K Ang; S M Lippman; W K Hong Journal: Cancer Date: 2001-04-01 Impact factor: 6.860
Authors: G Heiduschka; C Lill; S Schneider; R Seemann; G Kornek; R Schmid; U Kotowski; D Thurnher Journal: Strahlenther Onkol Date: 2014-02-21 Impact factor: 3.621
Authors: Matthias Uhl; Thomas Welzel; Jan Oelmann; Gregor Habl; Henrik Hauswald; Alexandra Jensen; Malte Ellerbrock; Jürgen Debus; Klaus Herfarth Journal: Strahlenther Onkol Date: 2014-03-25 Impact factor: 3.621
Authors: Kelly K Curtis; Helen J Ross; Ashley L Garrett; Theresa A Jizba; Ajay B Patel; Samir H Patel; William W Wong; Michele Y Halyard; Stephen J Ko; Heidi E Kosiorek; Robert L Foote Journal: Radiat Oncol Date: 2016-04-09 Impact factor: 3.481